03/05/2024  21:59:59 Var. +1.10 Volume Denaro- Lettera- Capitalizzazione di mercato Dividend Y. Rapporto P/E
401.08USD +0.28% 50,437
Fatturato: 20.24 mill.
-Quantità in denaro: - -Quantità in lettera: - 103.6 bill.USD - 28.55

Descrizione business

Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative medicines so people with serious diseases can lead better lives. In addition to its clinical development programs focused on cystic fibrosis, Vertex has more than a dozen ongoing research programs aimed at other serious and life-threatening diseases. Founded in 1989 in Cambridge, Mass., Vertex today has research and development sites and commercial offices in the United States, Europe, Canada and Australia. For five years in a row, Science magazine has named Vertex one of its Top Employers in the life sciences.
 

Consiglio di amministrazione & Consiglio di sorveglianza

CEO
Reshma Kewalramani, M.D.
Consiglio di amministrazione
Charles F. Wagner, Jr., David Altshuler, Stuart A. Arbuckle, Jonathan Biller, Carmen Bozic, Amit K. Sachdev, Bastiano Sanna, Nia Tatsis, E. Morrey Atkinson, Ph.D.
Consiglio di sorveglianza
Dr. Jeffrey Leiden, Bruce I. Sachs, Diana McKenzie, Dr. Alan Garber, Dr. Sangeeta N. Bhatia, Lloyd Carney, Reshma Kewalramani, Terrence C. Kearney, Suketu (Suky) Upadhyay
 

Dati aziendali

Name: Vertex Pharmaceuticals Inc.
Indirizzo: 50 Northern Avenue,Boston, Massachusetts 02210, USA
Telefono: +1-617-961-7163
Fax: -
E-mail: Investorinfo@VRTX.com
Internet: www.vrtx.com/
Industria: Healthcare
Settore: Pharmaceutical Industry
Sub settore: Pharmaceuticals
Fine dell'anno finanziario: 31/12
Flottante libero: 82.70%
Data dell'IPO: 24/07/1991

Rapporti con gli investitori

Name: Susie Lisa
IR telefono: +1-617-341-6108
IR Fax: -
IR e-mail: investorinfo@vrtx.com

Company calendar

CW 19 | 06/05/2024 Interim Report 1st Quarter/3 Months
 

Principali azionisti

Altri
 
52.58%
Blackrock Inc.
 
8.84%
Vanguard Group Inc
 
8.48%
Capital World Investors
 
6.72%
FMR, LLC
 
5.67%
State Street Corporation
 
4.78%
Wellington Management Group, LLP
 
2.93%
Alliancebernstein L.P.
 
2.92%
Price (T.Rowe) Associates Inc
 
2.62%
Altri
 
4.46%